Yasir Alayed1, Melanie Davidson2, Stanley Liu2, William Chu2, Eric Tseng2, Patrick Cheung2, Danny Vesprini2, Hans Cheung2, Gerard Morton2, H B Musunuru3, Anath Ravi2, Renee Korol2, Andrea Deabreu4, Ling Ho3, Kristina Commisso4, Zeeba Bhounr4, Laura D'Alimonte2, Nicole Mittmann5, Alice Dragomir6, Liang Zhang3, Andrew Loblaw7. 1. Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Division of Radiation Oncology, College of Medicine, King Saud University, Riyadh, Saudi Arabia. 2. Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada. 3. Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. 4. Clinical Trials and Epidemiology Program, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. 5. Cancer Care Ontario, Toronto, Ontario, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada. 6. Department of Surgery, McGill University, Montreal, Quebec, Canada. 7. Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. Electronic address: andrew.loblaw@sunnybrook.ca.
Abstract
PURPOSE: Dose-escalated stereotactic ablative radiotherapy (SABR) to the whole prostate may be associated with better outcomes but has a risk of increased toxicity. An alternative approach is to focally boost the dominant intraprostatic lesion (DIL) seen on magnetic resonance imaging. We report the toxicity and quality-of-life (QOL) outcomes of 2 phase 2 trials of prostate and pelvic SABR, with or without a simultaneous DIL boost. METHODS AND MATERIALS: The first trial treated patients with high-risk prostate cancer to a dose of 40 Gy to the prostate and 25 Gy to the pelvis in 5 fractions. The second trial treated patients with intermediate-risk and high-risk prostate cancer to a dose of 35 Gy to the prostate, 25 Gy to the pelvis, and a DIL boost up to 50 Gy in 5 fractions. Acute toxicities, late toxicities, and QOL were assessed. RESULTS: Thirty patients were enrolled in each trial. In the focal boost cohort, the median DIL D90% was 48.3 Gy. There was no significant difference in acute grade ≥2 gastrointestinal or genitourinary toxicity between the 2 trials or in cumulative worst late gastrointestinal or genitourinary toxicity up to 24 months. There was no significant difference in QOL domain scores or minimally clinical important change between the 2 trials. CONCLUSIONS: Prostate and pelvic SABR with a simultaneous DIL boost was feasible. Acute grade ≥2 toxicity, late toxicity, and QOL seemed to be comparable to a cohort that did not receive a focal boost. Further follow-up will be required to assess long-term outcomes, and randomized data are required to confirm these findings.
PURPOSE: Dose-escalated stereotactic ablative radiotherapy (SABR) to the whole prostate may be associated with better outcomes but has a risk of increased toxicity. An alternative approach is to focally boost the dominant intraprostatic lesion (DIL) seen on magnetic resonance imaging. We report the toxicity and quality-of-life (QOL) outcomes of 2 phase 2 trials of prostate and pelvic SABR, with or without a simultaneous DIL boost. METHODS AND MATERIALS: The first trial treated patients with high-risk prostate cancer to a dose of 40 Gy to the prostate and 25 Gy to the pelvis in 5 fractions. The second trial treated patients with intermediate-risk and high-risk prostate cancer to a dose of 35 Gy to the prostate, 25 Gy to the pelvis, and a DIL boost up to 50 Gy in 5 fractions. Acute toxicities, late toxicities, and QOL were assessed. RESULTS: Thirty patients were enrolled in each trial. In the focal boost cohort, the median DIL D90% was 48.3 Gy. There was no significant difference in acute grade ≥2 gastrointestinal or genitourinary toxicity between the 2 trials or in cumulative worst late gastrointestinal or genitourinary toxicity up to 24 months. There was no significant difference in QOL domain scores or minimally clinical important change between the 2 trials. CONCLUSIONS: Prostate and pelvic SABR with a simultaneous DIL boost was feasible. Acute grade ≥2 toxicity, late toxicity, and QOL seemed to be comparable to a cohort that did not receive a focal boost. Further follow-up will be required to assess long-term outcomes, and randomized data are required to confirm these findings.
Authors: Almudena Zapatero; Maria Roch; Pablo Castro Tejero; David Büchser; Carmen Martin de Vidales; Saturnino González; Pablo Rodríguez; Luis Alberto San Jose; Guillermo Celada; Maria Teresa Murillo Journal: Br J Radiol Date: 2021-09-19 Impact factor: 3.039
Authors: Luke Nicholls; Yae-Eun Suh; Ewan Chapman; Daniel Henderson; Caroline Jones; Kirsty Morrison; Aslam Sohaib; Helen Taylor; Alison Tree; Nicholas van As Journal: Clin Transl Radiat Oncol Date: 2020-10-20
Authors: Sarah O S Osman; Ciaran Fairmichael; Glenn Whitten; Gavin S Lundy; Rachel Wesselman; Melissa LaBonte Wilson; Alan R Hounsell; Kevin M Prise; Denise Irvine; Conor K McGarry; Suneil Jain Journal: Radiat Oncol Date: 2022-02-22 Impact factor: 3.481
Authors: Wei Liu; Andrew Loblaw; David Laidley; Hatim Fakir; Lucas Mendez; Melanie Davidson; Zahra Kassam; Ting-Yim Lee; Aaron Ward; Jonathan Thiessen; Jane Bayani; John Conyngham; Laura Bailey; Joseph D Andrews; Glenn Bauman Journal: Front Oncol Date: 2022-04-13 Impact factor: 5.738